Carlyle Group Inc. — Director's Dealing 2022

Aug 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2022-08-17

Reporting Person: Carlyle Group Inc. (10% Owner)
Reporting Person: Abingworth LLP (10% Owner)
Reporting Person: Abingworth Bioventures 8 LP (10% Owner)
Reporting Person: Carlyle Holdings I GP Inc. (10% Owner)
Reporting Person: Carlyle Holdings I GP Sub L.L.C. (10% Owner)
Reporting Person: Carlyle Holdings I L.P. (10% Owner)
Reporting Person: CG Subsidiary Holdings L.L.C. (10% Owner)
Reporting Person: TC Group, LLC (10% Owner)
Reporting Person: Carlyle Investment Management LLC (10% Owner)
Reporting Person: Carlyle Genesis UK LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-17	Class A Common Stock	M	9925	$11.00	Acquired	2970156	Indirect
2022-08-17	Class A Common Stock	S	3281	$19.8849	Disposed	2966875	Indirect
2022-08-17	Class A Common Stock	S	6472	$20.4201	Disposed	2960403	Indirect
2022-08-17	Class A Common Stock	S	172	$21.0748	Disposed	2960231	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-17	Stock Option (right to buy)	$11.00	M	9925	Disposed	2031-05-12	Class A Common Stock (9925)	Indirect

Footnotes

F1: Reflects securities held of record by Abingworth Bioventures 8 LP ("ABV 8"). ABV 8 has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV 8.

F2: The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV 8, but each disclaims beneficial ownership of such securities.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $19.995. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.99. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.025 to $21.09. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The stock option is fully vested and exercisable.

F7: Under an agreement between Kurt von Emster and Abingworth LLP, Mr. von Emster is deemed to hold the stock option and any shares of Class A Common Stock issuable upon exercise of the stock option for the benefit of ABV 8, and must exercise the stock option solely upon the direction of Abingworth LLP.